Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38207224.
- Also identified by DOI 10.1200/PO.23.00257.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Novel use of vandetanib in a child with aggressive MTC with prolonged response to treatment.
Medical subject headings
- Carcinoma, Neuroendocrine
- Thyroid Neoplasms